News
CASIF
0.129
0.00%
0.000
Weekly Report: what happened at CASIF last week (0914-0918)?
Weekly Report · 2d ago
Weekly Report: what happened at CASIF last week (0907-0911)?
Weekly Report · 09/14 10:26
Weekly Report: what happened at CASIF last week (0831-0904)?
Weekly Report · 09/07 10:20
CASI Pharmaceuticals Nets $5.9 Million From Sale of Alesta Stake to BioMarin
TipRanks · 09/02 11:27
Weekly Report: what happened at CASIF last week (0824-0828)?
Weekly Report · 08/31 10:27
Weekly Report: what happened at CASIF last week (0817-0821)?
Weekly Report · 08/24 10:28
Weekly Report: what happened at CASIF last week (0810-0814)?
Weekly Report · 08/17 10:29
CASI Pharmaceuticals Posts First-Half 2026 Results, Advances CID-103 After Nasdaq Delisting
TipRanks · 08/14 11:28
CASI Pharmaceuticals GAAP EPS of -$0.97, revenue of $9.8M
Seeking Alpha · 08/14 10:55
CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results
Barchart · 08/14 05:45
CASI Pharmaceuticals Continues U.S. Streamlining With Senior Vice President Departure
TipRanks · 08/13 21:14
Weekly Report: what happened at CASIF last week (0803-0807)?
Weekly Report · 08/10 10:23
Weekly Report: what happened at CASIF last week (0727-0731)?
Weekly Report · 08/03 10:23
Weekly Report: what happened at CASIF last week (0720-0724)?
Weekly Report · 07/27 10:28
Early-Stage CID-103 Trial Puts CASI Pharmaceuticals on Investors’ Watchlist
TipRanks · 07/22 16:31
Weekly Report: what happened at CASIF last week (0713-0717)?
Weekly Report · 07/20 10:24
Weekly Report: what happened at CASIF last week (0706-0710)?
Weekly Report · 07/13 10:26
Weekly Report: what happened at CASIF last week (0629-0703)?
Weekly Report · 07/06 10:30
CASI Pharmaceuticals Rescinds Evomela License Termination in Settlement With Acrotech
TipRanks · 06/29 10:57
Weekly Report: what happened at CASIF last week (0622-0626)?
Weekly Report · 06/29 10:24
More
Webull provides a variety of real-time CASIF stock news. You can receive the latest news about Casi Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About CASIF
CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.